Page 727 - medicina-integrativa_compress

742 PARTE II, SECCIÓN 12 DERMATOLOGÍA

55. Matsui EC, Wood RA, Rand C, et al: Mouse allergen exposure and 81. Van Gool CJ, Thijs C, Henquet CJ, et al: γ-Linolenic acid
mouse skin test sensitivity in suburban, middle-class children with supplementation for prophylaxis of atopic dermatitis: A randomized
asthma. J Allergy Clin Immunol 113:910-915, 2004. controlled trial in infants at high familial risk. Am J Clin Nutr
56. Daud LR, Garralda ME, David TJ: Psychosocial adjustment in 77:943-951, 2003.
preschool children with atopic eczema. Arch Dis Child 69:670-676, 82. Bombardelli E, Curri SB, Della Loggia R, et al: Anti-inflammatory
1993. activity of 18-β-glycyrrhetinic acid in Phytosome® form. Fitoterapia
57. White A, Horne DJ, Varigos GA: Psychological profile of the atopic 60(Suppl):29-37, 1989.
patient. Australas J Dermatol 31:13-16, 1990. 83. Teelucksingh S, Mackie AD, Burt D, et al: Potentiation of
58. Rostenberg A: Psychosomatic concepts in atopic dermatitis—a hydrocortisone activity in skin by glycyrrhetinic acid. Lancet
critique. Arch Dermatol 79:692-699, 1959. 335:1060-1063, 1990.
59. Buske-Kirschbaum A, Geiben A, Hellhammer D: Psychobiological 84. Saeedi M, Morteza-Semnani K, Ghoreishi MR: The treatment of atopic
aspects of atopic dermatitis: An overview. Psychother Psychosom dermatitis with licorice gel. J Dermatolog Treat 14:153-157, 2003.
70:6-16, 2001. 85. Belloni G, Pinelli S, Veraldi S: A randomized, double-blind,
60. Kodama A, Horikawa T, Suzuki T, et al: Effect of stress on atopic vehicle-controlled study to evaluate the efficacy and safety of
dermatitis: Investigation in patients after the great Hanshin MAS063D (Atopiclair®), in the treatment of mild to moderate
earthquake. J Allergy Clin Immunol 104:173-176, 1999. atopic dermatitis. Eur J Dermatol 1:31-36. 2005.
61. King RM, Wilson GV: Use of a diary technique to investigate 86. Schempp CM, Windeck T, Hezel S: Topical treatment of atopic
psychosomatic reactions in atopic dermatitis. J Psychosom Res dermatitis with St. John’s Wort cream: A randomized, placebo
35:697-706, 1991. controlled, double blind half-side comparison. Phytomedicine
62. Gupta MA, Gupta AK, Schork NJ, et al: Depression modulates 10:S31-S37, 2003.
pruritus perception: A study of pruritus in psoriasis, atopic 87. Brown DJ, Dattner AM: Phytotherapeutic approaches to common
dermatitis, and chronic idiopathic urticaria. Psychosom Med 56: dermatologic conditions. Arch Dermatol 134:1401-1404, 1998.
36-40, 1994. 88. Fuchs SM, Schliemann-Willers S, Fischer TW, et al: Protective
63. Buske-Kirschbaum A, Jobst S, Wustmans A, et al: Attenuated free effects of different marigold (Calendula officinalis L.) and rosemary
cortisol response to psychosocial stress in children with atopic cream preparations against sodium-lauryl-sulfate induced irritant
dermatitis. Psychosom Med 59:419-426, 1997. contact dermatitis. Skin Pharmacol Physiol 18:195-200, 2005.
64. Laue L, Lotze MT, Chroussos GP, et al: Effect of chronic treatment 89. Berberian BJ, Breneman DL, Drake LA, et al: The addition of topical
with the glucocorticoid antagonist RU 486 in man: Toxicity, doxepin to corticosteroid therapy: An improved treatment regimen
immunological and hormonal aspects. J Clin Endocrinol Metab for atopic dermatitis. Int J Dermatol 38:145-148, 1999.
71:1474-1480, 1990. 90. Chamlin SL, Kao J, Frieden IJ, et al: Ceramide-dominant barrier
65. Friedman EM, Irwin MRL: Modulation of immune cell function by repair lipids alleviate childhood atopic dermatitis: Changes in barrier
the autonomic nervous system. Pharmacol Ther 74:27-38, 1997. function provide a sensitive indicator of disease activity. J Am Acad
66. Szentivanyi A: The beta adrenergic theory of the atopic abnormality Dermatol 47:198-208, 2002.
in bronchial asthma. J Allergy 42:201-232, 1968. 91. Stucker M, Pieck C, Stoerb C, et al: Topical vitamin B12—a new
67. McCruden AB, Stimson WH: Sex hormones and immune function. therapeutic approach in atopic dermatitis: Evaluation of efficacy and
In Ader R, Felton DL, Cohen N (eds): Psychoneuroimmunology. tolerability in a randomized placebo-controlled multicentre clinical
San Diego, Academic, 1991, pp 475-493. trial. Br J Dermatol 150:977-983, 2004.
68. Carr DJ, Rogers TJ, Weber RJ: The relevance of opioids and opioid 92. Hanifin JM, Cooper KD, Ho VC, et al: Guidelines of care for atopic
receptors on immunocompetence and immune homeostasis. Proc dermatitis. J Am Acad Dermatol 50:391-404, 2004.
Soc Exp Biol Med 213:248-257, 1996. 93. Jutel M, Watanabe T, Klunker S, et al: Histamine regulates T-cell
69. Kelley KW: Growth hormone in immunobiology. In Ader R, Felton and antibody responses by differential expression of H1 and
DL, Cohen N (eds): Psychoneuroimmunology. San Diego, H2 receptors. Nature 413:420-425, 2001.
Academic, 1991, pp 377-402. 94. Yanase DJ, David-Bajar K: The leukotriene antagonist montelukast
70. Viljanen M, Savilahi E, Haahtela T, et al: Probiotics in the treatment as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol
of atopic eczema/dermatitis syndrome in infants: a double blind 44:89-93, 2001.
placebo controlled trial. Allergy 60:494-500, 2005. 95. Eustachio N, Alessandro P, Margherita F, et al: Efficacy and
71. Kalliomaki M, Salminen S, Poussa T, et al: Probiotics and tolerability of montelukast as a therapeutic agent for severe atopic
prevention of atopic disease: 4-year follow-up of a randomized dermatitis in adults. Acta Derm Venereol 82:297-298, 2002.
placebo-controlled trial. Lancet 361:1869-1871, 2003. 96. Lintu P, Savolainen J, Kortekangas-Savolainen O, et al: Systemic
72. Wright S, Burton JL: Oral evening-primrose-seed-oil improves ketoconazole is an effective treatment of atopic dermatitis with
atopic eczema. Lancet 2:1120-1122, 1982. IgE-mediated hypersensitivity to yeasts. Allergy 56:512-517, 2001.
73. Shalin-Karrila M, Mattila L, Jansen CT, et al: Evening primrose oil 97. Bleehan SS, Chu AC, Hamann I, et al: Fluticasone propionate
in the treatment of atopic eczema: Effect on clinical status, plasma 0.05% cream in the treatment of atopic eczema: A multicenter
phospholipids fatty acids and circulating blood prostaglandins. study comparing once-daily treatment and once-daily vehicle
Br J Dermatol 117:11-19, 1987. cream application versus twice-daily treatment.Br J Dermatol
74. Bordoni A, Biagi PL, Masi M, et al: Evening primrose oil (Efamol) in 133:592-597, 1995.
the treatment of children with atopic eczema. Drugs Exp Clin Res 98. Hanifin JT, Gupta AK, Rajagopalan R: Intermittent dosing of
14:291-297, 1987. fluticasone propionate cream for reducing the risk of relapse in
75. Biagi PL, Bordoni A, Masi M, et al: A long-term study on the use atopic dermatitis patients. Br J Dermatol 147:528-537, 2002.
of evening primrose oil (Efamol) in atopic children. Drugs Exp Clin 99. Freidlander SF, Herbert AA, Allen DB: Safety of fluticasone
Res 14:285-290, 1988. propionate cream 0.05% for the treatment of severe and extensive
76. Steward JCM, Morse PF, Moss M, et al: Treatment of severe and atopic dermatitis in children as young as 3 months. J Am Acad
moderately severe atopic dermatitis with evening primrose oil Dermatol 46:387-393, 2002.
(Epogam): A multi-centre study. J Nutr Med 2:9-15, 1991. 100. Tan MH, Lebwohl M, Esser AC, et al: The penetration of 0.005%
77. Bamford JTM, Ginbson RW, Renier CM: Atopic eczema fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol
unresponsive to evening primrose oil (linoleic and gamma-linolenic 45:392-396, 2001.
acids). J Am Acad Dermatol 13:959-965, 1985. 101. Aalto-Korte K, Turpeinen M: Bone mineral density in patients with
78. Bjørnboe A, Søyland E, Bjørnboe GE, et al: Effect of dietary atopic dermatitis. Br J Dermatol 136:172-175, 1997.
supplementation with eicosapentaenoic acid in the treatment of 102. Protopic® product Monograph. Markham, Ontario, Astellas Pharma
atopic dermatitis. Br J Dermatol 117:463-469, 1987. Canada, Inc, 4.1.05.
79. Berth-Jones J, Graham-Brown RAC: Placebo-controlled trial of 103. Elidel product Monograph. East Hanover, NJ, NovartisPharmaceuticals
essential fatty acid supplementation in atopic dermatitis. Lancet Corp, July 2004.
341:1557-1560, 1993. 104. Ashcroft DM, Dimmock P, Garside R, et al: Efficacy and tolerability
80. Henz BM, Jablonska S, Van de Kerkhof PCM, et al: Double-blind, of topical pimecrolimus and tacrolimus in the treatment of atopic
multicentre analysis of the efficacy of borage oil in patients with dermatitis: Meta-analysis of randomized controlled trials. Brit Med J
atopic eczema. Br J Dermatol 140:685-688, 1999. 330:516-524, 2005.